Mylotarg 4.5 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26F9Z17
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,450
Award facts
- Contract value 100% obligated
- $29,449.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,449.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp (parent company: Cencora, Inc.) on January 21, 2026, for the supply of Mylotarg 4.5 mg vials, with completion scheduled for February 11, 2026. This competitively awarded contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999 comprehensive pharmaceutical supply vehicle running through December 2026 that enables global pharmaceutical support for military healthcare programs.
As a major pharmaceutical distributor, AmerisourceBergen maintains a critical role in the federal medical supply chain, delivering a broad portfolio of specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency and other government healthcare systems. Mylotarg (gemtuzumab ozogamicin) is an oncology therapeutic used in the treatment of acute myeloid leukemia, reflecting the company's ongoing role in supplying specialized pharmaceutical commodities to military medical treatment facilities and veteran healthcare programs. The firm fixed-price structure and competitive award process demonstrate AmerisourceBergen's capability to meet federal procurement requirements for essential pharmaceutical products.
Quick answers
Who was awarded contract SPE2DR26F9Z17?
SPE2DR26F9Z17 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26F9Z17 worth?
The government has obligated $29,450 on SPE2DR26F9Z17.
Is contract SPE2DR26F9Z17 an order under another contract?
Yes. SPE2DR26F9Z17 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9Z17 competed?
The extent of competition for SPE2DR26F9Z17 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award